A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia - PubMed
5 days ago
- #STAT3
- #AML
- #venetoclax-resistance
- A STAT3 degrader shows efficacy in treating venetoclax-resistant acute myeloid leukemia (AML).
- STAT3 upregulation is identified as a key mechanism of resistance to venetoclax in AML.
- The STAT3 degrader KT-333 reduces STAT3 and MCL1 levels, corrects mitochondrial dysfunction, and induces apoptosis in resistant AML cells.
- STAT3 hyperactivation is leukemogenic and can be targeted therapeutically with specific degraders.
- The study suggests that STAT3 inhibition and indirect MCL1 downregulation could be promising for treating resistant AML and MDS.